The FDA reported preliminary results from a safety trial of the arthritis drug tofacitinib (Xeljanz, Xeljanz XR, Pfizer), showing increased risk for serious heart-related problems and cancer, compared with tumor necrosis factor (TNF) inhibitors.
FEBRUARY 8, 2021